{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Koch M"],"funding":["NCCIH NIH HHS","NIA NIH HHS","NINDS NIH HHS"],"pagination":["545-553"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6199693"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10"],"pubmed_abstract":["<h4>Introduction</h4>Apolipoproteins of demonstrated importance to brain cholesterol and ß-amyloid metabolism may serve as novel risk markers for Alzheimer's pathology.<h4>Methods</h4>We measured apolipoproteins (apoE, apoJ, apoA-I, and apoC-III and their uniquely defined subspecies) by enzyme-linked immunosorbent assay in plasma collected in 2000 and 2008 from 176 dementia-free participants of the Ginkgo Evaluation of Memory Study and related these to ß-amyloid on positron emission tomography scans, hippocampal volume, and white matter lesion volume in 2009.<h4>Results</h4>Higher apoE was associated with lower ß-amyloid deposition. Despite apoA-I being unrelated to hippocampal volume, subspecies of apoA-I containing or lacking apoJ or apoC-III showed opposite associations with hippocampal volume. Higher apoJ and apoE lacking apoJ were associated with higher hippocampal volume and higher white matter lesion volume, respectively. Associations were similar in participants without cognitive impairment or <i>APOE</i> ε4 noncarrier and when analyzing apolipoproteins in 2000-2002.<h4>Discussion</h4>Apolipoproteins may be important minimally invasive biomarkers indicative of Alzheimer's pathology."],"journal":["Alzheimer's & dementia (Amsterdam, Netherlands)"],"pubmed_title":["Apolipoproteins and Alzheimer's pathophysiology."],"pmcid":["PMC6199693"],"funding_grant_id":["U24 AG021886","P30 AG049638","R01 NS089638","P50 AG005133","U01 AT000162"],"pubmed_authors":["Koch M","Furtado JD","DeKosky ST","Kuller LH","Mukamal KJ","Lopez OL","Mackey RH","Hughes TM","Fitzpatrick AL","Jensen MK"],"additional_accession":[]},"is_claimable":false,"name":"Apolipoproteins and Alzheimer's pathophysiology.","description":"<h4>Introduction</h4>Apolipoproteins of demonstrated importance to brain cholesterol and ß-amyloid metabolism may serve as novel risk markers for Alzheimer's pathology.<h4>Methods</h4>We measured apolipoproteins (apoE, apoJ, apoA-I, and apoC-III and their uniquely defined subspecies) by enzyme-linked immunosorbent assay in plasma collected in 2000 and 2008 from 176 dementia-free participants of the Ginkgo Evaluation of Memory Study and related these to ß-amyloid on positron emission tomography scans, hippocampal volume, and white matter lesion volume in 2009.<h4>Results</h4>Higher apoE was associated with lower ß-amyloid deposition. Despite apoA-I being unrelated to hippocampal volume, subspecies of apoA-I containing or lacking apoJ or apoC-III showed opposite associations with hippocampal volume. Higher apoJ and apoE lacking apoJ were associated with higher hippocampal volume and higher white matter lesion volume, respectively. Associations were similar in participants without cognitive impairment or <i>APOE</i> ε4 noncarrier and when analyzing apolipoproteins in 2000-2002.<h4>Discussion</h4>Apolipoproteins may be important minimally invasive biomarkers indicative of Alzheimer's pathology.","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018","modification":"2024-11-09T06:07:59.864Z","creation":"2019-03-27T00:05:22Z"},"accession":"S-EPMC6199693","cross_references":{"pubmed":["30370330"],"doi":["10.1016/j.dadm.2018.07.001"]}}